Bing Yao. Viela Bio

On track for first au­toim­mune drug ap­proval, Bing Yao steers As­traZeneca spin­off to $150M IPO

Just days af­ter Viela Bio se­cured its first PDU­FA date for its lead au­toim­mune drug, the As­traZeneca spin­off is con­fi­dent­ly gun­ning for a $150 mil­lion IPO.

The biotech is ded­i­cat­ing most of the pro­ceeds to three as­sets — out of six it got from a cleanup at Med­Im­mune be­fore the bi­o­log­ics unit got re­struc­tured al­to­geth­er. Chief among them would be inebi­lizum­ab, the an­ti-CD19 drug that’s be­ing ush­ered through the BLA ap­proval process for neu­romyelitis op­ti­ca spec­trum dis­or­der, prepped for com­mer­cial­iza­tion and ex­plored in ad­di­tion­al in­di­ca­tions. Then there’s al­so the CD40L-tar­get­ing VIB4920, for which Phase II stud­ies are planned for lat­er this year; and the Phase Ib an­ti­body VIB7734, which in­hibits ILT7.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.